build, grow and invest in
that put patients first.
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The Company holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals. Harrow Health also owns royalty rights in four clinical‑stage drug candidates being developed by Surface and Melt.
At Harrow Health, we focus on pursuing opportunities for underserved markets. We are data driven, and we use our access to real-world clinical experiences to lower the investment risks of the work we do. We concentrate on the commercial appeal of high-value assets, and our objective is to make paradigm-shifting medicines available to patients as soon as possible. We believe our approach to finding high-value opportunities and balancing risk with real world experience can deliver exceptional value for our stakeholders.
Visionology intends to be the only online eye health company trusted by doctors and patients and will formally launch in 2021.
Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of patented non-intravenous and non-opioid sedation and analgesia medicines for short-duration medical procedures in outpatient and in-office settings. The Company recently completed its Phase 1 MELT study and expects to begin it’s Phase 2 clinical study in the third quarter of 2021. Harrow Health owns 3.5 million shares of Melt (approximately 44%).
Surface Ophthalmics, Inc. is focused on the > $1 billion ocular surface disease and related markets, including chronic, episodic, and refractory dry eye disease, pain and inflammation post ocular surgery, and blepharitis. Harrow owns 3.5 million shares of Surface (roughly 30% equity interest), which completed its Series A financing from Flying L Partners in May 2018.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved products and has six additional products that have been submitted to the FDA.
ImprimisRx is the nation’s leading ophthalmology pharmaceutical compounding business, serving thousands of ophthalmologists in all 50 states and providing access to novel medications at affordable prices.
Please contact us by filling out the form below and someone will get back to you as soon as possible.
Harrow Health is always interested in collaborating with development partners or manufacturers to bring new and innovative products to market. If you are interested in partnering with Harrow, please contact email@example.com